To achieve the clinical proof-of-principle for non-invasive beta-cell mass imaging with PET for determination of beta-cell mass.
To develop new tracers with a clear clinical perspective within the runtime of BetaImage for known promising targets for which no optimal tracers exist so far.
To increase the number of potential beta-cell imaging strategies in vivo and in vitro by identifying new targets that could be used for PET as well as other imaging techniques by definition of new targets using a Systems Biology approach to characterise the global receptome of beta-cells.
To develop new tracers for imaging of novel beta-cell targets as defined by the Systems Biology approach using in vitro and in vivo models (PET, SPECT, optical imaging, MRI).
To establish xf-FDOCT (Extended Field Fourier Domain Optical Coherence Tomography) as a highly efficient method for 3D in vitro and dynamic in vivo imaging of beta-cell mass, microscopic tracer distribution, islet size, and islets perfusion.
To establish a streamlined methodology to increase efficiency of high-throughput tracer characterisation.
To build up a strong and long-lasting European expertise in the field of molecular imaging of beta-cells by dissemination of expertise and knowledge acquired within BetaImage.
Project Flyer
.png)
Search
